StreetInsider.com News Articles

Form 4 Vor Biopharma Inc. For: Oct 02 Filed by: Kolchinsky Peter

Mon, 05 Oct 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20261005/27150370.html

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 18:00:00 -0400

BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 59,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,550 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 18:00:00 -0400

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

Tue, 29 Sep 2026 08:05:00 -0400

More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48

42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks

After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE

Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) --

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

Tue, 29 Sep 2026 08:05:00 -0400

More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48

42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks

After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE

Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) --

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

Tue, 29 Sep 2026 08:05:00 -0400

More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48

42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks

After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE

Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) --

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

Tue, 29 Sep 2026 08:05:00 -0400

More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48

42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks

After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE

Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) --

Vor Biopharma (VOR) Reiterated at Buy by Stifel on Telitacicept’s Potential for gMG

Mon, 28 Sep 2026 07:40:59 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $40.00 price target on Vor Biopharma, Inc. (NASDAQ: VOR).

The analyst commented, "In conjunction with Stifel’s Virtual I&I Forum, we moderated a discussion with CMO Jeremy Sokolove and CCO Dallan Murray – a discussion which focused on telitacicept’s dual BAFF/APRIL inhibition as a novel and potentially best-in-class mechanism for broad(er) B cell lineage modulation for the treatment of gMG and other strategically-relevant AIDs (i.e. SjD). While acknowledging P3 gMG data generated by China-based partner RemeGen and the prospects of placebo arm degradation in the ongoing global P3 UPSTREAM MG trial (1H27 TLR)

Form 4 Vor Biopharma Inc. For: Aug 24 Filed by: Kolchinsky Peter

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079743.html

This biotech stock still Wolfe's top pick as multiple catalysts loomh

Mon, 31 Aug 2026 08:00:00 -0400